INTRODUCTION
============

Hemangioma represents the most common benign hepatic neoplasm, with an estimated prevalence of 0.4 to 20% based on autopsy series \[[@b1-cmh-2017-0002],[@b2-cmh-2017-0002]\]. Most hemangiomas are small, asymptomatic and detected incidentally. They are commonly detected in women with a female: male ratio of up to 5:1, and are more prevalent in the third and fifth decades \[[@b1-cmh-2017-0002]\]. Giant hepatic hemangiomas, defined as hemangiomas larger than 4-5 cm, are frequently symptomatic and require intervention. Despite being pathologically benign, some hemangiomas grow in size by unclear mechanisms, and may be difficult to differentiate from malignant vascular tumors such as angiosarcomas. Moreover, diffuse hepatic hemangiomatosis usually presents in infancy with Rendu-Osler Weber disease or skeletal hemangiomatosis \[[@b3-cmh-2017-0002]\]. Isolated diffuse hepatic hemangiomatosis without extrahepatic lesions is extremely rare in adults. We experienced a case of living donor liver transplantation in a 50 year old female patient with hepatic hemangiomatosis and hepatic hemangioma with increased size and symptoms. Herein, we report this case with a review of literature.

CASE REPORT
===========

In May 27^th^, 2015, a 50 year old Korean woman was admitted due to dyspnea, abdominal pain and a palpable huge mass. At a previous routine health check in October 28^th^, 2010, a 10cm-sized giant hepatic hemangioma and several tiny hemangiomas less than 1cm in diameter were incidentally detected on ultrasonography and on subsequent abdominal computed tomography (CT) ([Fig. 1](#f1-cmh-2017-0002){ref-type="fig"}). However, she did not follow up the lesion after then. She didn't smoke or drink alcohol. Her medical history and familial history were unremarkable. She denied recent or remote estrogen administration or any other medications.

On admission, physical examination showed pale conjunctiva, and tender hepatomegaly which was palpated as palm breadth below the right costal margin. The laboratory tests showed hemoglobin level of 9.3 g/dL (MCV 77 fl, MCH 23.8 pg), platelet count of 123,000/mm^3^, total bilirubin of 0.4 mg/dL, alkaline phosphatase of 62 IU/L, gamma-glutamyl transpeptidase of 58 IU/L, aspartate transaminase of 28 IU/L, alanine transaminase of 20 IU/L, and a prothrombin time of 15.9 seconds, showing mild Kasabach-Merritt syndrome. Hepatitis B and C virus markers were negative and alpha feto-protein level was within normal range.

An abdomen CT taken on May 28^th^, 2015 demonstrated a 16 cm sized giant hemangioma in the central portion of the liver collapsing the inferior vena cava and heterogeneous nodular enhancement in the whole liver, with increased size and numbers of hemangiomas compared with the previous CT taken at 2010 ([Fig. 2](#f2-cmh-2017-0002){ref-type="fig"}). T2-weighted MR images demonstrated a huge mass with late, peripheral enhancement involving S1, 4, 7 and 8, and disseminated small enhancing lesions in the whole liver ([Fig. 3](#f3-cmh-2017-0002){ref-type="fig"}). Fluorodeoxyglucose positron emission tomography (FDG-PET) scan showed a large mass with diffuse isometabolism in the liver without abnormal extrahepatic hypermetabolic lesions. Under the impression of growing hemangiomatosis, transcatheter arterial embolization was performed, with the aim of improving the symptoms and decreaseing the size of the mass. Selective hepatic artery angiography showed multiple hypervascular tumor stains in both hemiliver. Embolization was done with poly-vinyl alcohol particles (PVA) of size 45-150 μm and 3 mm coil via several subsegmental branches (two A4 from LHA, A5, A1, A7) from both hepatic artery. A postembolization check angiogram still noted multiple hypervascular stains of in both lobes.

Due to the patient's pain and the growing speed of the tumor suggesting impending rupture, and as the extensive hepatic involvement precluded surgical resection, the only option left was liver transplantation, despite the low likelihood of a malignant vascular tumor. The patient's son wanted to donate his liver to her, and therefore living donor liver transplantation was decided. The surgeons planned to use a femoro-axillary bypass circulation to avoid massive bleeding risk during huge hemangioma-containing recipient liver hepatectomy, to minimize potential dissemination of malignant tumor cells through inferior vena cava, and to prevent severe bowel edema or ischemia after blocking portal flow during total hepatectomy, especially in this patient without collateral vessels related to previous portal hypertension. On July 14^th^, 2015, liver transplantation using a modified right graft was successfully performed under a femoro-axillary bypass system. The explanted liver weight was 2,344 g and the donor graft (right lobe) weighed 782 g. The total operative time was 575 minutes and the estimated blood loss was 1,100 mL. Transfusion was not needed for this patient.

Pathological evaluation of the surgical specimen confirmed a well-defined hemangioma in the form of a sponge-like reddish brown mass, and the remaining liver parenchyma had a similar small lesions ([Fig. 4](#f4-cmh-2017-0002){ref-type="fig"}, [5](#f5-cmh-2017-0002){ref-type="fig"}). She discharged on postoperative day 11 without any significant postoperative complications and is maintained on an immunosuppressive regimen of tacrolimus and mycophenolate in good health at the most recent follow up in December 2016.

DISCUSSION
==========

Hepatic hemangioma is the most common benign liver tumors incidentally detected in the majority of patients. However, the differential diagnosis of hepatic hemagioma includes other hypervascular tumors such as hepatocellular adenoma, epithelioid hemangioendothelioma, angiosarcoma, hepatocellular carcinoma, metastatic neuroendocrine tumor or metastatic renal cell carcinoma \[[@b3-cmh-2017-0002]\]. On the other hand, hepatic hemangiomatosis replacing the entire hepatic parenchyma is extremely rare in adults, while it is often reported in infants associated with Rendu-Osler Weber disease or skeletal hemangiomatosis \[[@b2-cmh-2017-0002]\]. Diagnostic biopsies for hemangiomas are not recommended due to the risk of hemorrhage and difficulty in definitive diagnosis even after biopsy \[[@b4-cmh-2017-0002]\]. Hepatic hemangiomas and hemangiomatosis are two separate entities with similar histological appearances. Co-existence of these entities in the same liver is rare and is described in the form of case reports \[[@b5-cmh-2017-0002]\].

Because most hemangiomas maintain stable size without growth during follow-up more than 5 years, frequent follow-up imaging for hemangioma is not advised \[[@b3-cmh-2017-0002]\]. However, the size of hepatic hemangioma increases in 10-20% of patients mostly due to vascular ectasia, leading to abdominal pain, intratumoral hemorrhage, rupture, compression of the biliary tree, cardiac failure from massive arteriovenous shunting or Kasabach-Merritt syndrome, which is characterized by consumptive coagulopathy presenting thrombocytopenia, microangiopathic hemolysis and disseminated intravascular coagulation \[[@b6-cmh-2017-0002]\]. Although rupture of hemangioma is very rare, it results in a high mortality. A few studies suggested that estrogen therapy may influence the growth of hemangioma, however, most cases did not support such relationship \[[@b7-cmh-2017-0002]\].

The treatment of symptomatic giant hepatic hemangioma is controversial. Surgical intervention is strictly reserved for complications of hemangioma or uncertainty of malignancy. Considering the severity of symptoms as treatment indications, the benefits and risks of surgical treatment should be considered. The size of the tumor per se cannot be a definite indication for surgery. Surgical technique includes enucleation or resection, depending on the localization, size, and number of lesions, growth pattern and diagnostic uncertainty. Nonsurgical therapy such as transarterial embolization or radiofrequency ablation is used to reduce the size of hemangioma and the alleviate symptoms.

Awareness of the presence of hepatic hemangiomatosis in patient with giant hepatic hemangioma is important for therapeutic decision. When the tumor exceeds a certain volume in patients with limited hepatic reserve, liver resection is precluded. Despite its complexity, liver transplantation should be considered for nonresectable benign hepatic neoplasms in patients with imminent life-threatening complications, an increased risk of malignant transformation, an underlying liver disease or the presence of severe symptoms. There have been 19 case reports of liver transplantation for giant hepatic hemangioma ([Table 1](#t1-cmh-2017-0002){ref-type="table"}) \[[@b8-cmh-2017-0002]-[@b21-cmh-2017-0002]\], including ours, with excellent results.

Our case showed that unresectable, progressively growing tumors with diffuse whole liver involvement complicated with severe abdominal pain forecasting impending rupture, and imminent Kasabach-Merritt syndrome. The only option for cure was to offer liver transplantation, however, her hepatic function was normal according to the model for end-stage liver disease (MELD) score system, so that she could not be a candidate for deceased donor liver transplantation. Therefore, this kind of case represents one of non-standard exception status, which should be approved by the Korean Network for Organ Sharing (KNOS) in the future.

We report a case of a 50 year old female patient presenting with rapidly growing, symptomatic giant hepatic hemangioma with diffuse hepatic hemangiomatosis who underwent successful living donor liver transplantation. To our best knowledge, this rare case is the first Korean case showing a malignant behavior of a benign hemangiomatosis requiring liver transplantation. This case represented an exceptional indication of deceased donor liver allocation despite the low MELD score. Further studies on the mechanism of growing hemangioma are warranted.
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![Initial CT scan of the abdomen and pelvis obtained on October 28, 2010. A huge (10-cm) hemangioma is evident in the central portion of the liver, with multiple disseminated small enhanced nodular lesions in the right hemiliver (A: arterial phase, B: delayed phase).](cmh-2017-0002f1){#f1-cmh-2017-0002}

![Follow-up CT scan of the abdomen and pelvis obtained on May 28, 2015. The mass in the central liver has enlarged, and numerous enhanced nodular lesions are disseminated in both hemilivers. The inferior vena cava (arrow) is massively dislocated to the left and slit-shaped due to compression (A: arterial phase, B: portal phase, C: delayed phase).](cmh-2017-0002f2){#f2-cmh-2017-0002}

![Liver MRI image obtained on June 3, 2015. T2-weighted MRI image shows the enlarged huge mass with a high signal intensity involving segments 1, 4, 7 and 8 of the liver. The extents of disseminated small enhanced lesions are increased (A: T2-weighted image, B: contrast-enhanced T1-weighted image).](cmh-2017-0002f3){#f3-cmh-2017-0002}

![The explanted liver showing multifocal patchy brownish discoloration. A representative section (A) demonstrates a relatively well-demarcated sponge-like reddish-brown mass (upper right). The remaining hepatic parenchyme also demonstrates punctate reddish-brown lesions (B).](cmh-2017-0002f4){#f4-cmh-2017-0002}

![The main mass (A) is relatively well-demarcated from the surrounding liver, and is composed of variable-sized vascular spaces, lined by benign endothelial cells, consistent with hemangioma (B). Multiple scattered small hemangiomas are present in the surrounding hepatic parenchyme (C) (A: H&E stain, ×10 magnification; B: H&E stain, ×200 magnification; C: H&E stain, ×100 magnification).](cmh-2017-0002f5){#f5-cmh-2017-0002}

###### 

Summary of the reported cases of liver transplantation for giant hepatic hemangioma

  Report no.   First author                                          Year        Age/Sex   Graft type       Presentation            Results
  ------------ ----------------------------------------------------- ----------- --------- ---------------- ----------------------- -------------------------------------
  1            Klompmaker, et al. \[[@b8-cmh-2017-0002]\] (1989)     1989        27Y/M     Whole            KMS                     Alive, 3 years
  2            Mora, et al. \[[@b9-cmh-2017-0002]\] (1995)           1995        42Y/F     Whole            KMS                     Discharged, 16 days after operation
  3            Tepetes, et al. \[[@b10-cmh-2017-0002]\] (1995)       1995        4wk/M     Whole            KMS                     Died, 8 days after operation
  4            Brouwers, et al. \[[@b11-cmh-2017-0002]\] (1997)      1980-1995   4 cases   Whole            2pain, 1rupture, 1KMS   1 Died, 1months after op.
                                                                                                                                    3 alive, 9 years
  5            Chui, et al. \[[@b12-cmh-2017-0002]\] (1996)          1996        2 cases   Whole            1 bleeding              1 alive, 18months
                                                                                                            1 pain                  1 alive, 14months
  6            Longeville , et al. \[[@b13-cmh-2017-0002]\] (1997)   1997        47Y/M     Whole            KMS                     Alive, 12 months
  7            Russo, et al. \[[@b14-cmh-2017-0002]\] (1997)         1997        43Y/F     Whole                                    Discharged, 14 days after operation
  8            Kumashiro, et al. \[[@b15-cmh-2017-0002]\] (2002)     2002        48Y/F     Posterior lobe   KMS                     Discharged, 15 days after operation
  9            Ferraz, et al. \[[@b16-cmh-2017-0002]\] (2004)        2004        25Y/F     Whole            KMS                     Alive, 30 months
  10           Meguro, et al. \[[@b17-cmh-2017-0002]\] (2008)        2006        45Y/F     Left lobe        KMS                     Alive, 10 months
  11           Zhong, et al. \[[@b18-cmh-2017-0002]\] (2014)         2007        27Y/F     Right lobe       Diffuse mass            Alive, 50 months
  12           Vagefi, et al. \[[@b19-cmh-2017-0002]\] (2011)        2010        39Y/F     Whole            Rupture, KMS            Alive
  13           Yildiz, et al. \[[@b20-cmh-2017-0002]\] (2014)        2014        44Y/F     Whole            KMS                     Alive, 1 months
  14           Lange, et al. \[[@b21-cmh-2017-0002]\] (2015)         2015        47Y/F     Whole            Diffuse mass            Alive

KMS, Kasabach-Merritt syndrome.
